STAT3 and neoplasm: We analyzed the tumor lysates to find out the ability of CNR2 activation to inhibit EGFR and IGF-IR activation in vivo and found that the JWH-015-treated group has less activation of EGFR, IGF-IR, STAT3, AKT and ERK proteins compared to control group (Figure 5D and Supp.